| Gene symbol | TTR | Synonyms | ATTR, CTS, CTS1, HEL111, HsT2651, PALB, TBPA, TTN | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | transthyretin | ||||
| GTO ID | GTC1993 |
| Trial ID | NCT03702829 |
| Disease | Amyloidosis |
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 416858|IONIS-FXIRX|FXI-ASO|ISIS-FXI Rx|BAY2306001||BAY2306001|Fesomersen |
| Phase | Phase2 |
| Recruitment status | Unknown |
| Title | 24 Month Open Label Study of the Tolerability and Efficacy of an Antisense Oligonucleotide (Inotersen) in Patients With Transthyretin (TTR) Amyloid Cardiomyopathy |
| Year | 2019 |
| Country | United States |
| Company sponsor | Brigham and Women's Hospital |
| Other ID(s) | 2018P001436 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||